[doi: 10.1063/1.3556781]“
“Informed by the findings from prospective observational studies and randomized outcome trials, guidelines for the management of hypertension acknowledge that the benefit of treatment can be attributed largely to blood pressure (BP) reduction. Therefore, quantification of differential BP lowering of different agents within classes of anti-hypertensives is of practical importance. The objective of this analysis was to compare the efficacy of candesartan and losartan with respect to reduction in systolic and diastolic BP (SBP and DBP). A systematic literature search of databases from 1980 to 1 October 2008 identified 13 studies in which Dactolisib molecular weight candesartan

and losartan were compared in randomized trials in hypertensive patients. Data from 4066 patients were included in the analysis using a random effect model. Mean changes in SBP and DBP were compared for each drug alone and after stratification for dose and for combination with hydrochlorothiazide (HCTZ). On the basis of all the data, the weighted

mean difference favoured candesartan-3.22 mm Hg (95% confidence interval (CI) 2.16, 4.29) for SBP and 2.21 mm Hg (95% CI 1.34, 3.07) for DBP. These findings were consistent when analyses according to dose and combination with HCTZ were carried out. Thus, it can be concluded that at currently recommended doses, candesartan is more effective than losartan in lowering BP.”
“Background and aim: The results from studies published on the association of fatty acid-binding protein 2 (FABP2) PF-03084014 price Ala54Thr polymorphism with body mass index (BMI) are conflicting. In this meta-analysis, we investigated the association of the FABP2 Ala54Thr polymorphism with BMI.

Methods and results: We searched for articles published prior to June 2009 using PubMed, HugeNavigator and China National Knowledge Internet. The

languages were limited to English and Chinese. Data on BMI were collected. A pooled weighted mean difference (WMD), together with 95% confidence interval (CI), was used for this meta-analysis.

A total of 27 studies with 10 974 subjects were included in this meta-analysis. The pooled effect for dominant, recessive and co-dominant model comparisons did not suggest the significant association between selleck inhibitor the FABP2 Ala54Thr polymorphism and BMI in overall populations: WMD(fixed) (effects) = -0.00, 95% CI: (-0.16 to 0.15), p = 0.99, WMD(random effects) = -0.00, 95% CI: (-0.16 to 0.15), p = 0.99, p(Q) = 0.77, I(2) = 0%, WMD(fixed effects) = -0.12, 95% CI: (-0.39 to 0.14), p = 0.35, WMD(random) (effects) = -0.12, 95% CI: (-0.39 to 0.14), p = 0.35, p(Q) = 0.47, I(2) = 0% and WMD(fixed) (effects) = 0.07, 95% CI: (-0.11 to 0.25), p = 0.45, WMD(random) (effects) = 0.07, 95% CI: (-0.11 to 0.25), p = 0.45, p(Q) = 0.90, I(2) = 0%, respectively.